

## DAFTAR PUSTAKA

1. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. *Critical care medicine*. 2013 Feb;41(2):580-637
2. Djoko W, Arya G. 2006. Penanganan Sepsis. *DEXA MEDIA Jurnal Kedokteran dan Farmasi* No. 2, Vol.19, April – Juni 2006
3. Cohen J. The Immunopathogenesis of Sepsis. *Nature*. 2002;420(6917):885-91
4. Wan L, Bagshaw SM, Langenberg C, Saotome T, May C, Bellomo R. Pathophysiology of Septic Acute Kidney Injury: what do we really know? *Critical care medicine* [Internet]. 2008 Apr [cited 2012 Dec 1];36(4 Suppl):S198–203. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18382194>
5. Acute Renal Failure and Sepsis - NEJM [Internet]. [cited 2012 Dec 1]. Available from: <http://www.nejm.org/doi/full/10.1056/NEJMra032401>
6. Gill N, Nally JV, Fatica RA. Renal Failure Secondary to Acute Tubular Necrosis: Epidemiology, Diagnosis, and Management. *Chest*. 2005;128(4):2847-63
7. Jacobson RH, Striker EG, Klahr S. The Principles and Practice of Nephrology. B.C. Decker, Inc. Philadelphia, 1991: 165-7

8. Thakar CV, Christianson A, Freyberg R, Almenoff P, Render ML. Incidence and Outcomes of Acute Kidney Injury in Intensive Care Units: a Veterans Administration study. *Critical care medicine*.2009;37(9):2552-8
9. Bagshaw SM, Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, et al. Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. *Clinical journal of the American Society of Nephrology : CJASN*.2007;2(3):431-9
10. Hoste EAJ, Lameire NH, Vanholder RC, Benoit DD, Decruyenaere JMA, Colardyn FA. Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome. *Journal of the American Society of Nephrology : JASN*.2003;14(4):1022-30
11. Bone RC, Balk RA, Cerra FB, et al. Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis ACCP/SCCM consensus conference. *Chest*. 1992;101:1644-55
12. Hall M, William S, DeFrances C, Golosinskiy A. Inpatient care for septicemia or sepsis: A challenge for patients and hospitals. 2011.
13. The Epidemiology of Sepsis in the United States from 1979 through 2000 - NEJM [Internet]. [cited 2012 Dec 1]. Available from: <http://www.nejm.org/doi/full/10.1056/NEJMoa022139>
14. Balk R, Goyette R. Multiple organ dysfunction syndrome in patients with severe sepsis: more than just inflammation. *International Congress and Symposium*. 2002; 249:37-58.

15. Sinto R, Nainggolan G. Acute kidney injury: Pendekatan klinis dan tata laksana. *Majalah Kedokteran Indonesia*. 2010;60(2):81-8
16. Bagshaw SM, George C, Bellomo R. A comparison of the RIFLE and AKIN criteria for acute kidney injury in critically ill patients. *Nephrol Dial Transplant*. 2008;23:1569-74
17. Bonventre JV. Pathophysiology of ischemic acute renal failure. In: Ronco C, Bellomo R, Brendolan A, eds. Sepsis, kidney, and multiple organ dysfunction. *Contrib nephrol*. Basel: Karger; 2004. p. 19-30
18. Brezis M, Rosen S: Hypoxia of the renal medulla: Its implications for disease. *N Engl J Med*. 1995;332:647–655
19. Piccinni P, Carraro R, Ricci Z. Acute renal failure in the intensive care unit. In: Ronco C, Bellomo R, Brendolan A, eds. Sepsis, kidney, and multiple organ dysfunction. *Contrib nephrol*. Basel: Karger; 2004. p. 12-8
20. Chawla LS, Abeli L, Mazhari R, et al. Identifying critical care ill patient at high risk for developing acute renal failure: A pilot study. In: *Kidney international*. 2005;68:2274-80
21. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. *Clinical chemistry*. 1992;38(10):1933-53
22. Marshall W. Creatinine (serum, plasma). *Association for Clinical Biochemistry*. 2012.
23. Kratz A, Pesce MA, Basner RC, Einstein AJ. APPENDIX: laboratory values of clinical importance. In: Longo DL, Kasper DL, Jameson JL,

- Fauci AS, Hauser SL, Loscalzo J, eds. *Harrison's principle of internal medicine*. 18<sup>th</sup> ed; 2012. p. 3585-610
24. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. *Critical care medicine*. 2008. P. 296-327.
  25. Mayhew MS. 2001. Management of Chronic Kidney Disease in Primary Care. *Medscape*, <http://www.medscape.com/viewarticle/420220>
  26. Sutedjo AY. 2006. Pemeriksaan kimia darah untuk faal ginjal. In: *Buku saku Mengenal Penyakit Melalui Hasil Pemeriksaan Laboratorium*, Amara Books, Yogyakarta, 77-82.
  27. Hendromartono. 1999. Consensus on The Management of Diabetes Mellitus (Perkeni 1998), In: *Surabaya Diabetes Update VI*, editors Tjokroprawiro A, Surabaya, 1-14.
  28. Devarajan P. Update on mechanisms of ischemic acute kidney injury. *J Am Soc Nephrol*. 2006;17:1503-20.
  29. Hewitt SM, Dear J, Star RA. Discovery of protein biomarkers for renal diseases. *J Am Soc Nephrol*. 2004;15:1677-89.
  30. Clarkson MR, Friedewald JJ, Joseph A E, Rabb H. Acute kidney injury. In: Brenner BM, penyunting. *Brenner and Rector's The Kidney*. Edisi ke-8. Philadelphia: Saunders Elsevier; 2004.h.943-76.
  31. Balk RA. Pathogenesis and management of multiple organ dysfunction or failure in severe sepsis and septic shock. *Critical Care Clinics*. 2000;16(2):337-52.

32. Moreno R, Takala J, Willats S, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. 1996;22:707-10.
33. Yegenaga I, Hoste E, Biesen WV, et al. Clinical characteristics of patients developing ARF due to sepsis/systemic inflammatory response syndrome: results of a prospective study. *In: American Journal of Kidney Diseases.* 2004;43(5):817-24.

## Lampiran

### Frequencies

**Jenis Kelamin Pasien**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Laki - laki	32	55.2	55.2	55.2
	Perempuan	26	44.8	44.8	100.0
	Total	58	100.0	100.0	

**Klasifikasi Umur**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	< 31 tahun	8	13.8	13.8	13.8
	31 - 40 tahun	8	13.8	13.8	27.6
	41 - 50 tahun	8	13.8	13.8	41.4
	51 - 60 tahun	15	25.9	25.9	67.2
	> 60 tahun	19	32.8	32.8	100.0
	Total	58	100.0	100.0	

### Explore

**Descriptives**

		Statistic	Std. Error
Kreatinin 1	Mean	1.9836	.33878
	95% Confidence Interval for Lower Bound	1.3052	
	Mean Upper Bound	2.6620	
	5% Trimmed Mean	1.5467	
	Median	1.2550	
	Variance	6.657	
	Std. Deviation	2.58010	

	Minimum	.38	
	Maximum	16.65	
	Range	16.27	
	Interquartile Range	1.34	
	Skewness	4.169	.314
	Kurtosis	20.283	.618
Kreatinin 2	Mean	2.1252	.31569
	95% Confidence Interval for Lower Bound	1.4930	
	Mean Upper Bound	2.7573	
	5% Trimmed Mean	1.7540	
	Median	1.3300	
	Variance	5.780	
	Std. Deviation	2.40425	
	Minimum	.12	
	Maximum	13.33	
	Range	13.21	
	Interquartile Range	1.53	
	Skewness	3.177	.314
	Kurtosis	11.538	.618
Kreatinin 3	Mean	2.7338	.37335
	95% Confidence Interval for Lower Bound	1.9862	
	Mean Upper Bound	3.4814	
	5% Trimmed Mean	2.3378	
	Median	1.8150	
	Variance	8.085	
	Std. Deviation	2.84333	
	Minimum	.20	
	Maximum	16.02	
	Range	15.82	
	Interquartile Range	2.44	
	Skewness	2.865	.314

Kurtosis	10.193	.618
----------	--------	------

### Tests of Normality

	Kolmogorov-Smirnov <sup>a</sup>			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Kreatinin 1	.267	58	.000	.525	58	.000
Kreatinin 2	.252	58	.000	.625	58	.000
Kreatinin 3	.205	58	.000	.694	58	.000

a. Lilliefors Significance Correction

### Descriptives

		Statistic	Std. Error	
Lab1trans	Mean	.1344	.04431	
	95% Confidence Interval for Mean	Lower Bound	.0457	
		Upper Bound	.2231	
	5% Trimmed Mean	.1139		
	Median	.0986		
	Variance	.114		
	Std. Deviation	.33746		
	Minimum	-.42		
	Maximum	1.22		
	Range	1.64		
	Interquartile Range	.43		
	Skewness	.903	.314	
	Kurtosis	1.254	.618	
Lab2trans	Mean	.1637	.04807	
	95% Confidence Interval for Mean	Lower Bound	.0675	
		Upper Bound	.2600	
	5% Trimmed Mean	.1599		
	Median	.1239		
	Variance	.134		
	Std. Deviation	.36611		



	Minimum		-92	
	Maximum		1.12	
	Range		2.05	
	Interquartile Range		.46	
	Skewness		.164	.314
	Kurtosis		1.165	.618
Lab3trans	Mean		.2748	.04933
	95% Confidence Interval for Lower Bound		.1761	
	Mean	Upper Bound	.3736	
	5% Trimmed Mean		.2760	
	Median		.2588	
	Variance		.141	
	Std. Deviation		.37567	
	Minimum		-.70	
	Maximum		1.20	
	Range		1.90	
	Interquartile Range		.52	
	Skewness		.036	.314
	Kurtosis		.337	.618

#### Tests of Normality

	Kolmogorov-Smirnov <sup>a</sup>			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Lab1trans	.093	58	.200*	.953	58	.025
Lab2trans	.089	58	.200*	.976	58	.307
Lab3trans	.056	58	.200*	.991	58	.937

a. Lilliefors Significance Correction

\*. This is a lower bound of the true significance.

## General Linear Model

### Multivariate Tests<sup>b</sup>

Effect		Value	F	Hypothesis df	Error df	Sig.	Partial Eta Squared
Time	Pillai's Trace	.248	9.245 <sup>a</sup>	2.000	56.000	.000	.248
	Wilks' Lambda	.752	9.245 <sup>a</sup>	2.000	56.000	.000	.248
	Hotelling's Trace	.330	9.245 <sup>a</sup>	2.000	56.000	.000	.248
	Roy's Largest Root	.330	9.245 <sup>a</sup>	2.000	56.000	.000	.248

a. Exact statistic

b. Design: Intercept

Within Subjects Design: Time

### Mauchly's Test of Sphericity<sup>b</sup>

Measure: MEASURE\_1

Within Subject's Effect	Mauchly's W	Approx. Chi-Square	df	Sig.	Epsilon <sup>a</sup>		
					Greenhouse-Geisser	Huynh-Feldt	Lower-bound
Time	.773	14.454	2	.001	.815	.835	.500

Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is proportional to an identity matrix.

a. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in the Tests of Within-Subjects Effects table.

b. Design: Intercept

Within Subjects Design: Time

### Tests of Within-Subjects Effects

Measure:MEASURE\_1

Source		Type III Sum of Squares	df	Mean Square	F	Sig.	Partial Eta Squared
Time	Sphericity Assumed	.637	2	.318	13.880	.000	.196
	Greenhouse-Geisser	.637	1.629	.391	13.880	.000	.196
	Huynh-Feldt	.637	1.671	.381	13.880	.000	.196
	Lower-bound	.637	1.000	.637	13.880	.000	.196
Error(Time)	Sphericity Assumed	2.614	114	.023			
	Greenhouse-Geisser	2.614	92.873	.028			
	Huynh-Feldt	2.614	95.224	.027			
	Lower-bound	2.614	57.000	.046			

### Estimated Marginal

#### Pairwise Comparisons

Measure:MEASURE\_1

(I) Time	(J) Time	Mean Difference (I-J)	Std. Error	Sig. <sup>a</sup>	95% Confidence Interval for Difference <sup>a</sup>	
					Lower Bound	Upper Bound
1	2	-.029	.021	.497	-.081	.022
	3	-.140*	.033	.000	-.221	-.059
2	1	.029	.021	.497	-.022	.081
	3	-.111*	.029	.001	-.183	-.039
3	1	.140*	.033	.000	.059	.221
	2	.111*	.029	.001	.039	.183

Based on estimated marginal means

a. Adjustment for multiple comparisons: Bonferroni.

\*. The mean difference is significant at the .05 level.

**BIODATA MAHASISWA****Identitas**

Nama : Leonardo  
NIM : G2A009035  
Tempat, tanggal lahir : Jakarta, 2 Agustus 1991  
Jenis kelamin : Laki – laki  
Alamat : Jl. Bukit Duri Permai blok C-11, Jakarta Timur  
Nomor telepon : (021) – 8501808  
Nomor HP : 0812 1075 288  
e-mail : leo.tanamas@hotmail.com

**Riwayat Pendidikan Formal**

1. SD	: 1997	Lulus tahun: 2003
2. SMP	: 2003	Lulus tahun: 2006
3. SMA	: 2006	Lulus tahun: 2009
4. FK UNDIP	:	Masuk tahun: 2009

**Keanggotaan Organisasi**

1. PRMK FK UNDIP	Tahun 2009 s/d 2013
------------------	---------------------

**Data Rekam Medik**

NO. CM	Jenis Kelamin	Pem. 1	Pem. 2	Pem. 3
C292190	Laki - laki	1.54	1.74	3.51
C286291	Laki - laki	1.71	1.58	2.1
C285131	Perempuan	0.5	1	1.06
C272181	Laki - laki	0.98	1.33	1.6
C320638	Laki - laki	16.65	13.33	16.02
C299378	Perempuan	0.61	0.4	0.83
C318918	Perempuan	1.08	1.76	1.84
C180328	Laki - laki	2.38	2.8	3.5
C294388	Laki - laki	2.37	2.51	5
B424608	Laki - laki	3.13	4.97	6.43
C318408	Perempuan	0.76	1.33	1.9
C289976	Laki - laki	0.87	0.96	1.3
C158795	Laki - laki	1.75	2.26	1.7
C296795	Laki - laki	1.23	1.86	6.36
C290355	Laki - laki	1.3	1.41	1.39
C115315	Perempuan	0.5	0.5	1
C272575	Laki - laki	1.9	1.11	1.05
C243965	Perempuan	1	1.79	2.2
C306937	Laki - laki	1.7	1.8	1.4
C324127	Perempuan	0.97	1.3	0.96
C324927	Laki - laki	2.39	2.45	3
C320377	Laki - laki	1.28	1.22	1.43
C323706	Laki - laki	0.92	1.11	1.59
C320965	Laki - laki	0.64	1.84	1.1
C313345	Perempuan	0.54	0.74	0.84
C322435	Laki - laki	1.38	0.76	0.7
C298578	Perempuan	2.21	2.76	2.7
C295158	Laki - laki	10.99	11.75	13.28
B381387	Perempuan	0.68	1.15	1.23
C295857	Perempuan	2.11	2.02	2.38
C050802	Laki - laki	3.3	2.7	2.1
C291522	Perempuan	1.17	0.72	0.67
C307703	Perempuan	1.57	0.8	2.04
C282263	Laki - laki	3.87	3.02	2.92
C270573	Perempuan	0.63	0.7	1.14
B216894	Laki - laki	2.9	2.7	3.54
C295964	Perempuan	1.05	1.1	1.37
C320141	Perempuan	1.34	1.39	1.37

C320941	Perempuan	0.82	0.87	0.64
C148841	Perempuan	0.38	0.12	0.27
C326011	Laki - laki	0.75	0.72	0.2
C321580	Laki - laki	1.76	2.19	3.24
C319000	Perempuan	0.38	0.32	0.48
C304242	Perempuan	0.5	0.54	5.9
C328502	Perempuan	4.91	5.21	4.38
C314833	Perempuan	0.72	0.7	0.96
C306603	Laki - laki	1.9	2.18	2.3
C178753	Laki - laki	6.08	6.47	7.03
C211743	Laki - laki	1.02	0.81	1.18
C230196	Perempuan	2.95	5.93	4.84
C322206	Laki - laki	1.23	2.3	3.06
C258918	Laki - laki	1.39	1.22	3.9
C300224	Perempuan	3.8	4.45	5.7
C322374	Laki - laki	0.97	0.71	0.85
C300581	Perempuan	0.81	0.99	1.79
C322007	Laki - laki	1.34	1.31	4.53
C295385	Laki - laki	0.95	1.05	2.16
C299614	Perempuan	0.49	0.5	0.6